Mayaro (MAYV) is an emerging arthropod-borne virus belonging to the Alphavirus genus of the family. Although forest-dwelling mosquitoes have been considered as its main vector, the virus has also been detected in circulating mosquitoes. Here we assess the susceptibility of and to infection with MAYV and their innate immune response at an early stage of infection. was more susceptible to infection with MAYV than Analysis of transcript levels of twenty immunity-related genes by real-time PCR in the midgut of both mosquitoes infected with MAYV revealed increased expression of several immune genes, including CLIP-domain serine proteases, the anti-microbial peptides defensin A, E, cecropin E, and the virus inducible gene. The regulation of certain genes appeared to be species-dependent. Infection of with MAYV resulted in increased levels of myeloid differentiation2-related lipid recognition protein () transcripts, as compared to . Increased expression levels of thio-ester-containing protein 22 () and Niemann-Pick type C1 () gene transcripts were observed in infected , but not . The differences in these gene expression levels during MAYV infection could explain the variation in susceptibility observed in both mosquito species.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832402 | PMC |
http://dx.doi.org/10.3390/v11100924 | DOI Listing |
NPJ Vaccines
December 2024
Instituto Politécnico Nacional, IPN. Av. Luis Enrique Erro s/n. Unidad Adolfo López Mateos, Mexico City, Mexico.
Virus-like particles (VLPs) are an established vaccine platform and can be strong immunogens capable of eliciting both humoral and cellular immune responses against a range of pathogens. Here, we show by cryo-electron microscopy that VLPs of Mayaro virus, which contain envelope glycoproteins E1-E2 and capsid, exhibit an architecture that closely resembles native virus. In contrast to monomeric and soluble envelope 2 (E2) glycoprotein, both VLPs as well as the adenovirus and modified vaccinia virus Ankara (MVA) vaccine platforms expressing the equivalent envelope glycoproteins E1-E2, and capsid induced highly neutralising antibodies after immunisation.
View Article and Find Full Text PDFACS Omega
December 2024
Physics Department, Laboratory of Biophysics and Nanosystems, Federal University of Maranhão, São Luís, MA 65085-580, Brazil.
Mayaro virus (MAYV) is an emerging mosquito-borne viral pathogen whose infection results in arthritogenic disease. Despite ongoing research efforts, MAYV biology is largely unknown. Physical virology can assess MAYV nanoparticle metastability, assembly/disassembly, and polymorphism, allowing us to understand virion architecture and dynamics.
View Article and Find Full Text PDFPLoS Negl Trop Dis
December 2024
Laboratório de Vírus, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Yellow fever virus (YFV) circulates in a sylvatic cycle between non-human primates (NHPs) and arboreal mosquitoes in Brazil. Passive monitoring of ill or deceased NHPs is a key component of the Brazilian yellow fever (YF) surveillance program. Samples from NHPs carcasses are usually suitable for molecular tests but not for serological assays.
View Article and Find Full Text PDFSci Rep
December 2024
Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA.
Chikungunya (CHIKV), o'nyong-nyong (ONNV), and Mayaro (MAYV) viruses are transmitted by mosquitoes and known to cause a debilitating arthritogenic syndrome. These alphaviruses have emerged and re-emerged, leading to outbreaks in tropical and subtropical regions of Asia, South America, and Africa. Despite their prevalence, there persists a critical gap in the availability of sensitive and virus-specific point-of-care (POC) diagnostics.
View Article and Find Full Text PDFInt J Mol Sci
October 2024
Department of Biotechnology, Molecular Biology Laboratory, Federal University of Tocantins, Gurupi 77410-570, Brazil.
Chikungunya and Mayaro fevers are viral infectious diseases characterized by fever and arthralgia, for which there are currently no effective vaccines or treatments. The urgent need for novel antiviral agents against Chikungunya virus (CHIKV) and Mayaro virus (MAYV) has led to interest in plant-based compounds that can disrupt the viral replication cycle. (L.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!